Home|Journals|Articles by Year|Audio Abstracts

Review Article

Efficacy and safety of eptinezumab as migraine preventive therapy: A systematic review and meta-analysis

I Made Oka Adnyana, Eric Hartono Tedyanto, I Putu Eka Widyadharma.

Cited by 0 Articles

Migraine is one of the most common types of primary headaches worldwide (about 20%) besides tension-type headaches. Several types of migraine medications have been introduced and used. Drugs acting on calcitonin gene-related proteins have been developed recently and have shown positive results. We conducted an updated meta-analysis to determine the efficacy and safety of eptinezumab as a migraine preventive therapy. Eight studies were found eligible and included in this review. We found that the use of eptinezumab (100 mg and 300 mg) for 24 weeks reduced the mean monthly migraine days (−1.89 vs. −1.52). The use of eptinezumab 100 mg also reduced the mean Headache Impact Test-6 score for 12 weeks significantly [−7.36 (95% CI −8.25 to −6.48), p < 0.00001]. The summarized results of the incidence of any events at each dose showed no significant difference (p = 0.07), and nasopharyngitis was the most frequently reported adverse event (n = 245). In conclusion, eptinezumab is safe and effective and can be considered as a migraine preventive therapy

Key words: eptinezumab, migraine, monoclonal antibody, placebo, preventive.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.